Mesoblast Limited Revenue Growth Rates (MESO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mesoblast Limited  (NASDAQ: MESO)
 

MESO's Revenue Growth by Quarter and Year

Mesoblast Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MESO Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 17.20
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 17.20

MESOs Annual Revenue
Mesoblast Limited's Revenue in the fiscal year 2025 $ 17.20 millions
Mesoblast Limited's Revenue in the fiscal year 2024 $ 5.90 millions
Mesoblast Limited's Revenue in the fiscal year 2023 $ 7.50 millions
Mesoblast Limited's Revenue in the fiscal year 2022 $ 10.21 millions
Mesoblast Limited's Revenue in the fiscal year 2021 $ 7.43 millions




MESO Revenue fourth quarter 2025 Y/Y Growth Comment
Mesoblast Limited achieved in the fourth quarter 2025, above Company average Revenue surge of 191.49% year on year, to $ 17.20 millions.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 12 other companies have achieved higher Revenue growth. While Mesoblast Limited' s Revenue doubling of 191.49% ranks overall at the positon no. 161 in the fourth quarter 2025.


MESO Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 191.49 % -21.33 % 252.11 % -10.5 %
3rd Quarter September - - - -58.22 %
2nd Quarter June - - - -
1st Quarter March - - -3.48 % 4.69 %
FY   191.49 % -37.5 % 67.38 % -

Financial Statements
Mesoblast Limited's fourth quarter 2025 Revenue $ 17.20 millions MESO's Income Statement
Mesoblast Limited's fourth quarter 2024 Revenue $ 5.90 millions Quarterly MESO's Income Statement


MESO Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - 42 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - -8.92 % -15.55 %
FY (Year on Year)   191.49 % -37.5 % 67.38 % -


Back to MESO Growth rate Comparisons >> Back to MESO Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #53
Overall #161

Revenue Y/Y Growth Statistics
High Average Low
876.86 % 57.49 % -100 %
(Jun 30 2022)   (Jun 30 2021)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #13
Healthcare Sector #53
Overall #161
Revenue Y/Y Growth Statistics
High Average Low
876.86 % 57.49 % -100 %
(Jun 30 2022)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Mesoblast Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MESO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


MESO's IV. Quarter Q/Q Revenue Comment


Mesoblast Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 17.20 $ 5.90 $ 7.50 $ 10.21 $ 7.43
Y / Y Revenue Growth (TTM) 191.39 % -21.32 % -26.54 % 37.36 % -76.88 %
Year on Year Revenue Growth Overall Ranking # 3105 # 3274 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 191.39 % -21.32 % -26.54 % 37.36 % -76.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 3105 # 3279 # 0 # 0 # 0


Cumulative Revenue growth Comment
Mesoblast Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 191.39% year on year, to $ 17 millions if the fiscal year would have ended in Jun 30 2025.
Mesoblast Limited's trailing twelve months Revenue growth was higher than company's average -21.93% and higher than -21.32% growth in Jun 30 2024.
The momentum is even more impressive from twelve months ended Jun 30 2024 exhibited at 191.39 % increase from $5.9 millions in the period from Jun 30 2024 to Jun 30 2021.

In the Healthcare sector 405 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3105, from total ranking in previous quarter at 3274.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 36
Healthcare Sector # 406
Overall # 3105

Revenue TTM Y/Y Growth Statistics
High Average Low
36.99 %
 -21.93 %
-76.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 406
S&P 500 # 3105
Cumulative Revenue growth Comment
Mesoblast Limited saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 191.39% year on year, to $ 17 millions if the fiscal year would have ended in Jun 30 2025.
Mesoblast Limited's trailing twelve months Revenue growth was higher than company's average -21.93% and higher than -21.32% growth in Jun 30 2024.
The momentum is even more impressive from twelve months ended Jun 30 2024 exhibited at 191.39 % increase from $5.9 millions in the period from Jun 30 2024 to Jun 30 2021.

In the Healthcare sector 405 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3105, from total ranking in previous quarter at 3274.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 36
Healthcare Sector # 406
Overall # 3105

Revenue TTM Y/Y Growth Statistics
High Average Low
36.99 %
-21.93 %
-76.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 406
S&P 500 # 3105




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MESO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions


About Mesoblast Limited Revenue Growth Rates (MESO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mesoblast Ltd (CIK 1345099).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001345099-26-000081
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mesoblast Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.